Introducing GPT-Rosalind for life sciences research
Summary (EN)
OpenAI announced GPT-Rosalind on April 16 as a new frontier reasoning model designed specifically for biology, drug discovery, and translational medicine. The company describes it as the first release in a broader life-sciences model series aimed at supporting scientific workflows rather than only general chat or coding use. According to OpenAI, GPT-Rosalind is optimized for tasks such as evidence synthesis, hypothesis generation, experimental planning, literature review, sequence-to-function interpretation, and data analysis across chemistry, genomics, proteins, pathways, and disease biology. OpenAI said the model is being released as a research preview through ChatGPT, Codex, and the API for qualified customers under a trusted-access program, and that it is also publishing a free Life Sciences research plugin for Codex that connects users to more than 50 scientific tools and data sources. The company cited benchmark gains on bioinformatics and research-task evaluations, and said it has been testing the system with organizations including Amgen, Moderna, the Allen Institute, and Thermo Fisher Scientific. OpenAI framed the launch around the idea that early-stage discovery is bottlenecked not only by scientific complexity but also by fragmented, tool-heavy workflows, and positioned GPT-Rosalind as an AI system intended to help scientists move more quickly from evidence gathering to experimentally grounded decisions while operating inside governed enterprise environments with added security and access controls.
Summary (ZH)
OpenAI 于 4 月 16 日发布 GPT-Rosalind，这是一款面向生命科学研究的新型前沿推理模型，重点覆盖生物学、药物发现与转化医学场景。OpenAI 将其定义为生命科学模型系列的首个版本，目标不是单纯提供通用问答能力，而是直接服务科学研究流程。根据官方说明，GPT-Rosalind 针对证据整合、假设生成、实验设计、文献检索、序列到功能解释以及复杂数据分析等任务进行了优化，可在化学、基因组学、蛋白质工程、通路分析和疾病相关生物学等领域提供更强支持。该模型目前以 research preview 形式向符合条件的客户开放，可通过 ChatGPT、Codex 和 API 使用，并纳入 trusted-access 部署框架。与此同时，OpenAI 还推出了免费的 Codex 生命科学研究插件，可连接 50 多个科研工具与数据源。OpenAI 公布了一系列基准测试结果，强调其在生物信息学和真实研究任务上的表现提升，并表示已与 Amgen、Moderna、Allen Institute、Thermo Fisher Scientific 等机构合作评估应用。官方将此次发布的核心意义归结为，用 AI 缩短从证据搜集到实验决策的路径，在受控企业环境中提升科研效率，同时加强安全、权限和治理机制，降低高风险误用可能性。